Aucta Pharmaceuticals, Inc. (AUCTA, Latin-improved, enhanced) is a research-driven specialty pharmaceutical company dedicated to developing, manufacturing, and commercializing innovative medicines through the 505(b)(2) pathway.   

Our focus is on addressing high unmet clinical needs in therapeutic areas such as central nervous system (CNS) disorders, metabolic diseases, and orphan indications. By leveraging established molecules with proven safety profiles, we aim to accelerate innovation, improve patient outcomes, and bridge critical gaps in healthcare access.

Aucta has operations in both New Jersey, U.S and Shanghai, China.